Helius Medical (HSDT) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

HSDT Stock Forecast


Helius Medical stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

HSDT Analyst Ratings


Buy

According to 3 Wall Street analysts, Helius Medical's rating consensus is 'Buy'. The analyst rating breakdown for HSDT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2024Maxim GroupBuyReduceDowngrade
Dec 20, 2022Maxim Group-BuyInitialise
Nov 17, 2022Zacks Investment Research-BuyUpgrade
Aug 24, 2022Roth Capital-BuyInitialise
Row per page
Go to

Helius Medical's last stock rating was published by Maxim Group on Oct 16, 2024. The company Downgrade its HSDT rating from "Buy" to "Reduce".

Helius Medical Financial Forecast


Helius Medical Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue---------$143.00K$256.00K$111.00K$282.00K$196.00K$119.00K$190.00K$258.00K$109.00K$71.00K$84.00K$191.00K$131.00K$133.00K$207.00K$152.00K$150.00K$518.00K$677.00K
Avg Forecast$301.00K$225.00K$239.00K$205.00K$268.00K$150.00K$150.00K$110.00K$249.67K$345.00K$188.33K$275.00K$262.33K$167.50K$360.00K$160.00K$100.00K$84.50K$95.00K$93.50K$170.00K$100.00K$100.00K$300.00K$200.00K$300.00K$300.00K$150.00K
High Forecast$301.00K$225.00K$239.00K$205.00K$268.00K$150.00K$150.00K$110.00K$249.67K$345.00K$188.33K$275.00K$262.33K$167.50K$360.00K$160.00K$100.00K$84.50K$95.00K$93.50K$170.00K$100.00K$100.00K$300.00K$200.00K$300.00K$300.00K$150.00K
Low Forecast$301.00K$225.00K$239.00K$205.00K$268.00K$150.00K$150.00K$110.00K$249.67K$345.00K$188.33K$275.00K$262.33K$167.50K$360.00K$160.00K$100.00K$84.50K$95.00K$93.50K$170.00K$100.00K$100.00K$300.00K$200.00K$300.00K$300.00K$150.00K
# Analysts1111111121111111111111111111
Surprise %---------0.41%1.36%0.40%1.07%1.17%0.33%1.19%2.58%1.29%0.75%0.90%1.12%1.31%1.33%0.69%0.76%0.50%1.73%4.51%

Helius Medical's average Quarter revenue forecast for Dec 23 based on 2 analysts is $249.67K, with a low forecast of $249.67K, and a high forecast of $249.67K. HSDT's average Quarter revenue forecast represents a 74.59% increase compared to the company's last Quarter revenue of $143.00K (Sep 23).

Helius Medical EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111111121111111111111111111
EBITDA---------$-2.22M$-3.22M$-4.97M$-321.00K$-4.03M$-2.98M$-4.71M$-4.03M$-3.98M$-6.29M$-3.54M$-3.37M$-3.75M$-3.91M$-3.08M$-5.76M$-5.83M$-11.40M$-14.93M
Avg Forecast$-301.00K$-225.00K$-239.00K$-205.00K$-268.00K$-150.00K$-150.00K$-110.00K$-249.67K$-345.00K$-188.33K$-275.00K$-262.33K$-167.50K$-360.00K$-4.20M$-100.00K$-84.50K$-4.21M$-93.50K$-170.00K$-100.00K$-100.00K$-300.00K$-200.00K$-300.00K$-300.00K$-150.00K
High Forecast$-301.00K$-225.00K$-239.00K$-205.00K$-268.00K$-150.00K$-150.00K$-110.00K$-249.67K$-345.00K$-188.33K$-275.00K$-262.33K$-167.50K$-360.00K$-3.36M$-100.00K$-84.50K$-3.37M$-93.50K$-170.00K$-100.00K$-100.00K$-300.00K$-200.00K$-300.00K$-300.00K$-150.00K
Low Forecast$-301.00K$-225.00K$-239.00K$-205.00K$-268.00K$-150.00K$-150.00K$-110.00K$-249.67K$-345.00K$-188.33K$-275.00K$-262.33K$-167.50K$-360.00K$-5.04M$-100.00K$-84.50K$-5.06M$-93.50K$-170.00K$-100.00K$-100.00K$-300.00K$-200.00K$-300.00K$-300.00K$-150.00K
Surprise %---------6.43%17.09%18.09%1.22%24.03%8.27%1.12%40.27%47.15%1.49%37.86%19.80%37.46%39.08%10.26%28.79%19.44%38.01%99.55%

undefined analysts predict HSDT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Helius Medical's previous annual EBITDA (undefined) of $NaN.

Helius Medical Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111111121111111111111111111
Net Income---------$-3.66M$-1.65M$-1.08M$-7.19M$2.96M$-4.57M$-3.91M$-4.10M$-4.69M$-5.98M$-3.36M$-2.53M$-3.48M$-3.36M$-4.76M$-4.80M$-5.59M$-186.00K$1.32M
Avg Forecast$-1.26M$-1.31M$-1.28M$-2.22M$-2.22M$-2.67M$-1.26M$-12.69M$-9.50M$-15.11M$-14.69M$-13.85M$-16.37M$-26.44M$-141.01M$-4.27M$-146.05M$-220.33M$-4.26M$-190.11M$-352.53M$-396.60M$-528.80M$-705.06M$-925.39M$-969.46M$-991.49M$2.62M
High Forecast$-1.26M$-1.31M$-1.28M$-2.22M$-2.22M$-2.67M$-1.26M$-12.69M$-9.50M$-15.11M$-14.69M$-13.85M$-16.37M$-26.44M$-141.01M$-3.42M$-146.05M$-220.33M$-3.41M$-190.11M$-352.53M$-396.60M$-528.80M$-705.06M$-925.39M$-969.46M$-991.49M$3.15M
Low Forecast$-1.26M$-1.31M$-1.28M$-2.22M$-2.22M$-2.67M$-1.26M$-12.69M$-9.50M$-15.11M$-14.69M$-13.85M$-16.37M$-26.44M$-141.01M$-5.12M$-146.05M$-220.33M$-5.11M$-190.11M$-352.53M$-396.60M$-528.80M$-705.06M$-925.39M$-969.46M$-991.49M$2.10M
Surprise %---------0.24%0.11%0.08%0.44%-0.11%0.03%0.92%0.03%0.02%1.40%0.02%0.01%0.01%0.01%0.01%0.01%0.01%0.00%0.51%

Helius Medical's average Quarter net income forecast for Dec 22 is $-16.37M, with a range of $-16.37M to $-16.37M. HSDT's average Quarter net income forecast represents a -653.89% decrease compared to the company's last Quarter net income of $2.96M (Sep 22).

Helius Medical SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111111121111111111111111111
SG&A---------$2.20M$2.57M$2.87M$1.97M$3.39M$2.46M$2.82M$2.38M$2.86M$4.74M$2.20M$2.09M$2.37M$2.39M$2.86M$3.81M$4.29M$3.85M$4.58M
Avg Forecast$4.63M$3.46M$3.68M$3.15M$4.12M$2.31M$2.31M$1.69M$3.84M$5.31M$2.90M$4.23M$4.04M$2.58M$5.54M$2.46M$1.54M$1.30M$1.46M$1.44M$2.61M$1.54M$1.54M$4.61M$3.08M$4.61M$4.61M$2.31M
High Forecast$4.63M$3.46M$3.68M$3.15M$4.12M$2.31M$2.31M$1.69M$3.84M$5.31M$2.90M$4.23M$4.04M$2.58M$5.54M$2.46M$1.54M$1.30M$1.46M$1.44M$2.61M$1.54M$1.54M$4.61M$3.08M$4.61M$4.61M$2.31M
Low Forecast$4.63M$3.46M$3.68M$3.15M$4.12M$2.31M$2.31M$1.69M$3.84M$5.31M$2.90M$4.23M$4.04M$2.58M$5.54M$2.46M$1.54M$1.30M$1.46M$1.44M$2.61M$1.54M$1.54M$4.61M$3.08M$4.61M$4.61M$2.31M
Surprise %---------0.41%0.89%0.68%0.49%1.32%0.44%1.15%1.54%2.20%3.25%1.53%0.80%1.54%1.56%0.62%1.24%0.93%0.83%1.99%

Helius Medical's average Quarter SG&A projection for Dec 23 is $3.84M, based on 2 Wall Street analysts, with a range of $3.84M to $3.84M. The forecast indicates a 74.88% rise compared to HSDT last annual SG&A of $2.20M (Sep 23).

Helius Medical EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111111121111111111111111111
EPS---------$-5.49$-0.00$-0.04$-0.26$0.35$-1.16$-1.03$-1.31$-2.28$-2.42$-1.51$-1.12$-2.41$-2.32$-7.09$-6.05$-7.17$14.96$23.85
Avg Forecast$-0.50$-0.52$-0.51$-0.88$-0.88$-1.06$-0.50$-5.04$-3.77$-6.00$-5.83$-5.50$-6.50$-10.50$-56.00$-56.50$-58.00$-87.50$-80.75$-75.50$-140.00$-157.50$-210.00$-280.00$-367.50$-385.00$-393.75$-446.25
High Forecast$-0.50$-0.52$-0.51$-0.88$-0.88$-1.06$-0.50$-5.04$-3.77$-6.00$-5.83$-5.50$-6.50$-10.50$-56.00$-56.50$-58.00$-87.50$-80.75$-75.50$-140.00$-157.50$-210.00$-280.00$-367.50$-385.00$-393.75$-446.25
Low Forecast$-0.50$-0.52$-0.51$-0.88$-0.88$-1.06$-0.50$-5.04$-3.77$-6.00$-5.83$-5.50$-6.50$-10.50$-56.00$-56.50$-58.00$-87.50$-80.75$-75.50$-140.00$-157.50$-210.00$-280.00$-367.50$-385.00$-393.75$-446.25
Surprise %---------0.92%0.00%0.01%0.04%-0.03%0.02%0.02%0.02%0.03%0.03%0.02%0.01%0.02%0.01%0.03%0.02%0.02%-0.04%-0.05%

According to 1 Wall Street analysts, Helius Medical's projected average Quarter EPS for Dec 22 is $-6.50, with a low estimate of $-6.50 and a high estimate of $-6.50. This represents a -1957.14% decrease compared to HSDT previous annual EPS of $0.35 (Sep 22).

Helius Medical Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BJDXBluejay Diagnostics$0.07$10.0014185.71%Buy
HSDTHelius Medical$0.51$5.00880.39%Buy
RPIDRapid Micro Biosystems$1.08$8.00640.74%Hold
AZYOElutia$1.49$10.25587.92%Buy
SGHTSight Sciences$4.66$10.25119.96%Hold
HSCSHeart Test Laboratories$2.73$3.009.89%Buy

HSDT Forecast FAQ


Yes, according to 3 Wall Street analysts, Helius Medical (HSDT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of HSDT's total ratings.

Helius Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $678K (high $678K, low $678K), average EBITDA is $-678K (high $-678K, low $-678K), average net income is $-18.835M (high $-18.835M, low $-18.835M), average SG&A $10.43M (high $10.43M, low $10.43M), and average EPS is $-7.48 (high $-7.48, low $-7.48). HSDT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $970K (high $970K, low $970K), average EBITDA is $-970K (high $-970K, low $-970K), average net income is $-6.069M (high $-6.069M, low $-6.069M), average SG&A $14.92M (high $14.92M, low $14.92M), and average EPS is $-2.41 (high $-2.41, low $-2.41).

Based on Helius Medical's last annual report (Dec 2023), the company's revenue was $644K, which missed the average analysts forecast of $1.06M by -39.13%. Apple's EBITDA was $-12.428M, beating the average prediction of $-1.058M by 1074.67%. The company's net income was $-8.85M, missing the average estimation of $-53.148M by -83.35%. Apple's SG&A was $9.27M, missing the average forecast of $16.27M by -43.03%. Lastly, the company's EPS was $-0.0146, missing the average prediction of $-21.107 by -99.93%. In terms of the last quarterly report (Sep 2023), Helius Medical's revenue was $143K, missing the average analysts' forecast of $345K by -58.55%. The company's EBITDA was $-2.218M, beating the average prediction of $-345K by 542.90%. Helius Medical's net income was $-3.663M, missing the average estimation of $-15.108M by -75.76%. The company's SG&A was $2.2M, missing the average forecast of $5.31M by -58.62%. Lastly, the company's EPS was $-5.49, missing the average prediction of $-6 by -8.50%